
Mozart Therapeutics secures $25M expansion to Series A; LianBio unveils PhIIa data for gastric cancer treatment
Mozart Therapeutics, a Seattle-based biotech centered on developing CD8 treg modulators to treat autoimmune and inflammatory diseases, has raised $25 million from new investors to extend its Series A. Mozart’s existing investors include Sofinnova Partners, Eli Lilly & Company, ARCH Venture Partners, Merck’s MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.